source
- Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapyThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, but tri…BioSpace · 50m ago↗ source
- Replimune’s twice-rejected melanoma drug prevails in FDA adcommFollowing a pair of FDA rejections for its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.Fierce Biotech · 5h ago↗ source
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.